CORRELATION OF IRON AND MYELOPEROXIDASE LEVELS IN ISCHEMIC HEART DISEASE
Objective: The objective of the study was to estimate, compare, and correlate serum iron and myeloperoxidase (MPO) levels in acute ischemic heart disease (IHD) cases.
Methods: Subjects for the study were divided into two groups of 35 acute IHD cases and 35 age and sex matched controls. Serum iron and MPO levels were assayed, and results compared.
Statistical analysis: The comparison between two groups was done using the Student’s t-test. Correlation between iron and MPO was established using Pearson’s correlation test.
Results: High serum MPO levels and low iron levels were observed in acute IHD cases in comparison to controls. There was no significant correlation between serum iron and MPO in acute IHD cases.
Conclusion: High iron levels have a beneficial role, whereas high MPO levels have an inflammatory role in the development of IHD. Determination of serum iron and MPO levels in high-risk subjects may help in taking proper measures to prevent acute IHD.
2. Rajeev G, Soneil G, Krishna K, Arvind G, Prakash D. Regional variations in cardiovascular risk factors in India: India heart watch. World J Cardiol 2012;4:112-20.
3. Adeyemi OS, Sulaiman AF, Akanji MA. Iron and Nitric Oxide in Anemia of Chronic Disease, Anemia; 2012. Available from: https:// www.intechopen.com/books/anemia/iron-and-nitric-oxide-in-anemia-of-chronic-disease-acd.
4. Adeyemi OS, Akanji MA. Iron and nitric oxide play key roles in the development of cardiovascular disorder. J Toxicol Environ Health Sci 2011;3:249-53.
5. Loria V, Dato I, Graziani F, Biasucci LM. Myeloperoxidase: A new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm 2008;2008:135625.
6. Singh TP, Nigam AK, Gupta AK, Singh B. Cardiac biomarkers: When to test ? -Physician perspective. J Indian Acad Clin Med 2011;12:117-21.
7. Roger KS, Leonard PZ, Tom T, Peter JS. Myeloperoxidase: A useful biomarker for cardiovascular disease risk stratification? Clin Chem 2009;55:1462-70.
8. Meuwese MC, Stroes ES, Hazen SL, Miert JN, Kuivenhoven JA, Schaub RG, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals. The EPIC-Norfolk prospective population study. J Am Coll Cardiol 2007;50:159-65.
9. Siedel J, Wahlefeld AW, Ziegenhorn J. A new iron ferrozine reagent without deproteinization. Clin Chem 1984;30:975.
10. Matheson NR, Wong PS, Travis J. Isolation and properties of human neutrophil myeloperoxidase. Biochemistry 1981;20:325-30.
11. Akheel MM, Mubashir BA, Dixit MD. Prevalence of risk factors of ischemic heart disease among students of J N medical college in Belgaum, Karnataka, India. Glob J Med Public Health 2012;1:24-6.
12. Daga LC, Kaul U, Mansoor A. Approach to STEMI and NSTEMI. J Assoc Physicians India 2011;59:19-25.
13. Antman EM, Braunwald E. ST-segment elevation myocardial infarction. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, editors. Harrison’s Principles of Internal Medicine. New York: McGraw Hill; 2008. p. 1532-4.
14. Delporte C, Antwerpen P, Vanhamme L, Roumeguère T, Boudjeltia KZ. Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies. Mediators Inflamm 2013;2013:971579.
15. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 1999;103:1547-60.
16. Hameed RM, Saifullah PH, Ewadh MJ. A new correlation between myeloperoxidase and lipid profile in ischemic heart disease patients. J Kerbala Univ 2007;5:68-75.
17. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Schomig A, Kastrati A. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest 2008;38:90-6.
18. Kaya MG, Yalcin R, Okyay K, Poyraz F, Bayraktar N, Pasaoglu H, et al. Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction. Tex Heart Inst J 2012;39:500-6.
19. Scharnagl H, Kleber ME, Genser B, Kickmaier S, Renner W, Weihrauch G, et al. Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography-the LURIC study. Int J Cardiol 2014;174:96-105.
20. Shetty S, Kumari NS, Madhu LN. Variations in serum myeloperoxidase levels with respect to hyperglycemia, duration of diabetes, BMI, sex and aging in Type 2 diabetes mellitus. Int J Res Pharm Biomed Sci 2012;3:652-5.
21. Karakas M, Koenig W, Zierer A, Herder C, Rottbauer W, Baumert J, et al. myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: Results from the MONICA/KORA Augsburg study. J Intern Med 2012;271:43-50.
22. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286:2136-42.
23. Roman RM, Camargo PV, Borges FK, Rossini AP, Polanczyk CA. Prognostic value of myeloperoxidase in coronary artery disease: Comparison of unstable and stable angina patients. Coron Artery Dis 2010;21:129-36.
24. Wong ND, Gransar H, Narula J, Shaw L, Moon JH, Miranda-Peats R, et al. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC Cardiovasc Imaging 2009;2:1093-9.
25. Van der Zwan LP, Scheffer PG, Dekker JM, Stehouwer CD, Heine RJ, Teerlink T. Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure. Hypertension 2010;55:1366-72.
26. Nahon P, Sutton A, Rufat P, Ziol M, Akouche H, Laguillier C, et al. Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis. Hepatology 2009;50:1484-93.
27. Kervinen H, Tenkanen L, Palosuo T, Roivainen M, Manninen V, Manttari M. Serum iron, infection and inflammation; effects on coronary risk. Scand Cardiovasc J 2004;38:345-8.
28. Liao Y, Cooper RS, McGee DL. Iron status and coronary heart disease: Negative findings from the NHANES I epidemiologic follow-up study. Am J Epidemiol 1994;139:704-12.
29. Ekblom K, Marklund SL, Jansson JH, Hallmans G, Weinehall L, Hultdin J. Iron stores and HFE genotypes are not related to increased risk of first-time myocardial infarction: A prospective nested case-referent study. Int J Cardiol 2011;150:169-72.
30. Huang CH, Chang CC, Kuo CL, Huang CS, Chiu TW, Lin CS, et al. Serum iron concentration, but not hemoglobin, correlates with TIMI risk score and 6-month left ventricular performance after primary angioplasty for acute myocardial infarction. PLoS One 2014;9:e104495.
31. Marniemi J, Jarvisalo J, Toikka T, Raiha I, Ahotupa M, Sourander L. Blood vitamins, mineral elements and inflammation markers as risk factors of vascular and non-vascular disease mortality in an elderly population. Int J Epidemiol 1998;27:799-807.
32. Hameed RM, Saifullah PH, Ewadh MJ. Evaluation of new correlation between myeloperoxidase-AB and trace elements in sera of ischemic heart disease patients. Med J Babylon 2007;4:205-18.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.